SAGE logo

Sage Therapeutics (SAGE) Company Overview

Profile

Full Name:

Sage Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 18, 2014

Indexes:

Not included

Website:

http://www.sagerx.com

Description:

Sage Therapeutics, Inc. is a biopharmaceutical company that specializes in the development and commercialization of drugs for the treatment of central nervous system disorders (depression, neuropsychiatric and neurological deviations). Founded in 2010, the company started its operations as Sterogen Biopharma, Inc. in 2011, changed its name to the current one. The corporate headquarters is located in Cambridge, Massachusetts. At the moment, the company has one product that was approved by the FDA in March 2019, and its commercialization began in the second half of that year. ZULRESSO is a drug whose active ingredient is identical to a natural neuroactive steroid. It is used for the treatment of postpartum depression.

Key Details

Price

$7.69

Market Cap

$472.79 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$41.24 M(-52.30% YoY)

Annual EPS

-$6.59(+27.18% YoY)

PE Ratio

-

Annual ROE

-63.37%

Annual Debt To Equity

0.00

Beta

1.60

Events Calendar

Earnings

Next earnings date:

Apr 25, 2025

Recent quarterly earnings:

Feb 11, 2025

Recent annual earnings:

Feb 11, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 12, 25 Wedbush
Neutral
Feb 12, 25 Scotiabank
Sector Outperform
Feb 12, 25 Needham
Hold
Feb 12, 25 HC Wainwright & Co.
Neutral
Feb 12, 25 Canaccord Genuity
Hold
Jan 2, 25 Piper Sandler
Overweight
Dec 16, 24 Stifel
Hold
Nov 21, 24 TD Cowen
Hold
Nov 21, 24 RBC Capital
Sector Perform
Nov 20, 24 Needham
Hold

Screeners with SAGE included

Growing Shares Outstanding
US stocks
Stocks with high beta
Stocks below SMA 200
Stocks recommended to hold
Best performing stocks last 3 months
Stocks above SMA 50
Stocks below analysts price target
Healthcare sector
All stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$7.69
SAGE price is $7.69

Price All-time High

$192.33
SAGE price is currently -96.00% below its historical high of $192.33

Price Analysts Target

$8.00
SAGE price is currently -3.88% lower than the consensus analysts' forecast

Price Today Change

+5.49%
SAGE price is up +5.49% today

Price YTD Change

+41.62%
SAGE price is up +41.62% since January 1st

Price 3-Year Change

-75.25%
SAGE price is down -75.25% over the past 3 years

Market cap

Market Cap

$472.79 M
SAGE market capitalization is $472.79 million

Market Cap 3-Year Change

-74.23%
SAGE market capitalization is down -74.23% over the past 3 years

Market Cap All-time High

$9.78 B
SAGE market capitalization is currently -95.16% below its historical high of $9.78 billion

Market Cap Sector Rank

67.22%
SAGE market capitalization is higher than 67.22% of companies in Healthcare sector

Technical

Beta

1.60
SAGE beta is 1.60

200-day SMA

$7.94
SAGE price is currently -3.14% below its 200-day simple moving average

14-day RSI

59.38
SAGE 14-day relative strength index is 59.38

30-day Relative Volume

1.12
SAGE 30-day relative volume is 1.12

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$41.24 M
SAGE annual revenue is $41.24 million

Annual Revenue Analysts Estimate

$82.13 M
SAGE annual revenue is currently -49.78% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

-52.3%
SAGE annual revenue is down -52.3% year-on-year

Annual Revenue Sector Rank

43.76%
SAGE annual revenue is higher than 43.76% of companies in Healthcare sector

Profit

Annual Gross Profit

$31.80 M
SAGE annual gross profit is $31.80 million

Annual Gross Margin

77.10%
SAGE annual gross profit margin is 77.10%

Annual Operating Profit

-$410.52 M
SAGE annual operating income is -$410.52 million

Annual Operating Margin

-995.36%
SAGE annual operating profit margin is -995.36%

Annual Net Income

-$400.67 M
SAGE annual net profit is -$400.67 million

Annual Net Margin

-971.48%
SAGE annual net profit margin is -971.48%

EPS

Annual EPS

-$6.59
SAGE annual earnings per share is -$6.59

Annual EPS Analysts Estimate

-$3.72
SAGE annual earnings per share is currently +77.27% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+27.18%
SAGE annual earnings per share is up +27.18% year-on-year

Annual EPS Sector Rank

18.26%
SAGE annual earnings per share is higher than 18.26% of companies in Healthcare sector

ROA & ROE

Annual ROA

-56.06%
SAGE annual return on assets is -56.06%

Annual ROE

-63.37%
SAGE annual return on equity is -63.37%

EBIT & EBITDA

Annual EBIT

-$410.52 M
SAGE annual earnings before interest & taxes is -$410.52 million

Annual EBITDA

-$409.49 M
SAGE annual EBITDA is -$409.49 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
SAGE price to earnings ratio value is unknown

PE Ratio Sector Rank

-
SAGE price to earnings ratio is unknown

PB Ratio

PB Ratio

1.02
SAGE price to book ratio is 1.02

PB Ratio Sector Rank

43.86%
SAGE price to book ratio is higher than 43.86% of companies in Healthcare sector

PS Ratio

PS Ratio

11.46
SAGE price to sales ratio is 11.46

PS Ratio Sector Rank

80.13%
SAGE price to sales ratio is higher than 80.13% of companies in Healthcare sector

Enterprise value

Enterprise Value

$403.60 M
SAGE enterprise value is $403.60 million

Enterprise Value Sector Rank

65.45%
SAGE enterprise value is higher than 65.45% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.99
SAGE EV/EBITDA is -0.99

EV/EBITDA Sector Rank

45.4%
SAGE EV/EBITDA is higher than 45.4% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

7.42
SAGE annual current ratio is 7.42

Annual Quick Ratio

-
SAGE annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
SAGE annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
SAGE annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

1
SAGE piotroski f-score is 1

Altman Z-Score

-5.54
SAGE altman z-score is -5.54

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$547.22 M
SAGE annual total assets is $547.22 million

Annual Non Current Assets

$15.92 M
SAGE annual long term assets is $15.92 million

Annual Current Assets

$531.30 M
SAGE annual total current assets is $531.30 million

Annual Cash & Cash Equivalents

$81.02 M
SAGE annual cash & cash equivalents is $81.02 million

Equity

Annual Book Value

$465.09 M
SAGE annual book value is $465.09 million

Annual Working Capital

$459.69 M
SAGE annual working capital is $459.69 million

Liabilities

Annual Total Liabilities

$82.13 M
SAGE annual total liabilities is $82.13 million

Annual Total Long Term Liabilities

$10.52 M
SAGE annual total long term liabilities is $10.52 million

Annual Current Liabilities

$71.61 M
SAGE annual total current liabilities is $71.61 million

Annual Accounts Payable

$12.70 M
SAGE annual accounts payable is $12.70 million

Debt

Annual Total Debt

$11.84 M
SAGE annual total debt is $11.84 million

Annual Total Debt 1-Year Change

+129.16%
SAGE annual total debt is up +129.16% year-on-year

Annual Long Term Debt

$10.52 M
SAGE annual long term debt is $10.52 million

Annual Short Term Debt

$1.32 M
SAGE annual short term debt is $1.32 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$451.76 M
SAGE annual total expenses is $451.76 million

Annual Operating Expenses

$442.31 M
SAGE annual total operating expenses is $442.31 million

Annual Cost Of Goods Sold

$9.44 M
SAGE annual cost of goods sold is $9.44 million

Annual SGA

$216.42 M
SAGE annual SGA is $216.42 million

Annual D&A

$1.03 M
SAGE annual depreciation & amortization is $1.03 million

Annual Interest Expense

-
SAGE annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$267.19 M
SAGE annual cash flow from operations is -$267.19 million

Annual CFO 1-Year Change

+50.57%
SAGE annual cash flow from operations is up +50.57% year-on-year

Annual CFI

$266.68 M
SAGE annual cash flow from investing activities is $266.68 million

Annual CFI 1-Year Change

-39.79%
SAGE annual cash flow from investing activities is down -39.79% year-on-year

Annual CFF

$10.66 M
SAGE annual cash flow from financing activities is $10.66 million

Annual CFF 1-Year Change

+76.92%
SAGE annual cash flow from financing activities is up +76.92% year-on-year

Free CashFlow

Annual FCF

-$267.19 M
SAGE annual free cash flow is -$267.19 million

Annual FCF 1-Year Change

+50.62%
SAGE annual free cash flow is up +50.62% year-on-year

CAPEX

Annual CAPEX

-
SAGE annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
SAGE annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

INNV logo
InnovAge Holding (INNV)
SNDA logo
Sonida Senior Living (SNDA)
TBRG logo
TruBridge (TBRG)
URGN logo
UroGen Pharma (URGN)
SVRA logo
Savara (SVRA)
Upstream Bio (UPB)
TBPH logo
Theravance Biopharma (TBPH)
STOK logo
Stoke Therapeutics (STOK)
SVA logo
Sinovac Biotech (SVA)

FAQ

  • What is the ticker symbol for Sage Therapeutics?
  • Does Sage Therapeutics pay dividends?
  • What sector is Sage Therapeutics in?
  • What industry is Sage Therapeutics in?
  • What country is Sage Therapeutics based in?
  • When did Sage Therapeutics go public?
  • Is Sage Therapeutics in the S&P 500?
  • Is Sage Therapeutics in the NASDAQ 100?
  • Is Sage Therapeutics in the Dow Jones?
  • When was Sage Therapeutics's last earnings report?
  • When does Sage Therapeutics report earnings?
  • Should I buy Sage Therapeutics stock now?

What is the ticker symbol for Sage Therapeutics?

The ticker symbol for Sage Therapeutics is NASDAQ:SAGE

Does Sage Therapeutics pay dividends?

No, Sage Therapeutics does not pay dividends

What sector is Sage Therapeutics in?

Sage Therapeutics is in the Healthcare sector

What industry is Sage Therapeutics in?

Sage Therapeutics is in the Biotechnology industry

What country is Sage Therapeutics based in?

Sage Therapeutics is headquartered in United States

When did Sage Therapeutics go public?

Sage Therapeutics's initial public offering (IPO) was on July 18, 2014

Is Sage Therapeutics in the S&P 500?

No, Sage Therapeutics is not included in the S&P 500 index

Is Sage Therapeutics in the NASDAQ 100?

No, Sage Therapeutics is not included in the NASDAQ 100 index

Is Sage Therapeutics in the Dow Jones?

No, Sage Therapeutics is not included in the Dow Jones index

When was Sage Therapeutics's last earnings report?

Sage Therapeutics's most recent earnings report was on Feb 11, 2025

When does Sage Therapeutics report earnings?

The next expected earnings date for Sage Therapeutics is Apr 25, 2025

Should I buy Sage Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions